期刊文献+

二甲双胍联合吡格列酮治疗48例初发2型糖尿病的疗效观察 被引量:15

下载PDF
导出
摘要 目的:观察二甲双胍联合吡格列酮治疗初发2型糖尿病的临床疗效。方法:采用随机数字表法将95例初发2型糖尿病患者分为两组,对照组给予口服盐酸二甲双胍片治疗,治疗组给予口服盐酸二甲双胍片联合盐酸吡格列酮片治疗,两组均治疗1个月为1疗程,3个疗程后对比临床疗效和不良反应。结果:两组治疗后FPG、2hPG和GHbA1c与治疗前比较差异有统计学意义(P<0.01);两组治疗后BMI、TG、TC、HDL-C和LDL-C均有所改善,比较差异无统计学意义(P>0.05);治疗组不良反应发生率4.17%与对照组6.38%比较差异无统计学意义(P>0.05)。结论:二甲双胍联合吡格列酮能够通过不同机制明显改善初发2型糖尿病的血糖水平和糖化血红蛋白水平,疗效确切,不良反应发生率低,在提高患者的生存治疗和改善预后方面具有非常重要的意义,值得临床继续探讨。
作者 肖向阳
出处 《中国医学创新》 CAS 2013年第4期37-38,共2页 Medical Innovation of China
  • 相关文献

参考文献5

二级参考文献24

  • 1张莉静,卢曦.基于PPAR抗糖尿病药物的研究进展[J].国外医学(药学分册),2004,31(5):287-291. 被引量:21
  • 2杨媚,杨刚毅,李伶,李清明,阮华玲,阳皓,李钶,孙勤,唐毅,Gunther Boden.不同糖耐量个体血浆内脂素水平的变化[J].中华内分泌代谢杂志,2006,22(3):245-247. 被引量:76
  • 3Fukuhara A, Matsuda M, Nishizawa M, et at. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science,2005,307 : 426-430.
  • 4Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett, 2006,580 : 2917-2921.
  • 5Filippatos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest, 2007,30 : 323-326.
  • 6Lopez-Bermejo A, Chieo-Julia B, Fernandez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes, 2006,55: 2871-2875.
  • 7Jian WX, Luo TH, Gu YY, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med, 2006,23 : 967-973.
  • 8Zhang YY, Gottardo L, Thompson R, et al. A visfatin promoter polymorphism is associated with low grade inflammation and type 2 diabetes. Obesity (Silver Spring), 2006,14 : 2119-2126.
  • 9Hsieh CH, He CT, Lee CH,et al. Both slow-release and regularform metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism, 2007,56:1087-1092.
  • 10MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab, 2007,9:490-497.

共引文献20

同被引文献100

  • 1李鸿娟,张东辉,刘海津.吡格列酮联合二甲双胍对2型糖尿病患者胰岛素抵抗及脂肪细胞因子水平的影响[J].中国老年学杂志,2014,34(9):2416-2417. 被引量:25
  • 2郝亚荣,韩其蔚,袁武堂,何小俊.吡格列酮对老年2型糖尿病患者的作用[J].武汉大学学报(医学版),2006,27(1):104-107. 被引量:7
  • 3马天,张坤.二甲双胍联合瑞格列奈与单纯胰岛素强化治疗的疗效比较[J].河北医学,2013,35(7):985-987.
  • 4Burke J, Kovacs B, Borton L, et al. Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment[J]. Postzrad Med. 2012. 124 (2) : 77-91.
  • 5Inzucchi S E.Oral antihyperglycemic therapy for type 2 diabetes: scientific review[Jl.JAMA, 2002, 287(3): 360-372.
  • 6Cvetkovic R S, Plosker G L.Exenatide: a review of its use in patients with type 2 diabetes mellitus(as an adiunet to mefformin and/or asulfonylurea)[J]. Drugs, 2007, 67(3): 935-954.
  • 7Xu Y, Wang L, He J, et al.Prevalennce and control of diabetes in Chinese adults[J].JAMA, 2013; 310 (9) : 948-959.
  • 8Deacon CF, Hoist JJ.Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes[J].Int J BiochemCellBiol, 2006, 38 (5-6): 831-844.
  • 9Lambeir AM, Durinxc C, Scharpe S, et al.Dipeptidyl- peptidase IV from bench to bedside:an update on structural properties, functions, and clinical aspects of the enzyme DPP IV ~J].Crit Rev Clin Lab Sci, 2003, 40 ( 3 ) : 209-294.
  • 10Xu Y, Wang L, He J, et al.Prevalennce and control of diabetes in Chinese adults[J].JAMA, 2013; 310 (9) : 948-959.

引证文献15

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部